Chimeric antigen receptor-modified T cells strike back

摘要: Chimeric antigen receptors (CARs) are engineered molecules designed to endow a polyclonal T-cell population with the ability recognize tumor-associated surface antigens. In their simplest form, CARs comprise targeting moiety in form of single-chain variable fragment from an antibody connected various intracellular signaling domains allowing for activation. This powerful approach combines specificity cytotoxic T cell. There has been much excitement since early phase trials CAR-T cells CD19 expressed on B-cell malignancies demonstrated remarkable efficacy inducing long-term, stable remissions otherwise relapsed/refractory disease. Despite these successes, we have just begun understand intricacies CAR biology efforts underway utilize this platform treatment other, previously refractory malignancies. Challenges currently include identification viable cancer targets, management strategies potentially severe and irreversible toxicities overcoming immunosuppressive nature tumor microenvironment. review will focus basic structure function, previous success new approaches aimed at broader application CAR-T-cell therapy.